![PDF) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study PDF) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study](https://i1.rgstatic.net/publication/333940583_Influence_of_patient_and_tumor_characteristics_on_therapy_persistence_with_letrozole_in_postmenopausal_women_with_advanced_breast_cancer_results_of_the_prospective_observational_EvAluate-TM_study/links/5d0d895192851cf44040e2b8/largepreview.png)
PDF) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study
![Cancers | Free Full-Text | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer Cancers | Free Full-Text | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer](https://www.mdpi.com/cancers/cancers-12-00574/article_deploy/html/images/cancers-12-00574-g001.png)
Cancers | Free Full-Text | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer
![PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)](https://i1.rgstatic.net/publication/343051230_Overall_survival_results_from_the_randomized_phase_2_study_of_palbociclib_in_combination_with_letrozole_versus_letrozole_alone_for_first-line_treatment_of_ERHER2-_advanced_breast_cancer_PALOMA-1_TRIO-/links/5f17d599299bf1720d58dd64/largepreview.png)
PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
![A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). - Abstract - Europe PMC A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). - Abstract - Europe PMC](https://europepmc.org/articles/PMC6522303/bin/nihms-1520009-f0001.jpg)